Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation develops and commercializes ophthalmic pharmaceutical and medical technology products for glaucoma, corneal disorders, and retinal diseases. News about Glaukos regularly covers financial results, global commercial execution, and updates for its dropless platform technologies, including iDose TR for sustained intracameral glaucoma drug delivery and Epioxa for corneal cross-linking in keratoconus.
Recurring company developments include FDA labeling actions for iDose TR, CMS coding and commercial availability updates for Epioxa, scientific presentations in ophthalmology, and quarterly sales trends across its glaucoma franchise. Company background also includes Micro-Invasive Glaucoma Surgery products such as iStent, iStent inject W, and iStent infinite, along with a pipeline aimed at chronic eye diseases.
Glaukos (NYSE:GKOS) announced that its management will participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation, where applicable, will be available in the Investors section of the Glaukos website.
Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year-over-year (49% constant currency), with glaucoma net sales of $155.2 million and U.S. glaucoma sales of $118.5 million, up 64% year-over-year. GAAP gross margin was approximately 82% and non-GAAP gross margin approximately 85%.
GAAP loss from operations was $17.3 million and GAAP net loss $18.4 million or ($0.31) per share, while non-GAAP net loss was $8.3 million or ($0.14) per share, including a $1.5 million acquired IPR&D charge. Glaukos ended Q2 2026 with about $289.3 million in cash, equivalents, short-term investments and restricted cash, and no debt, and raised its 2026 net sales guidance to $680–$700 million from $620–$635 million.
Glaukos (NYSE:GKOS) announced completion of patient enrollment in its U.S. 510(k) pivotal study of the PRESERFLO MicroShunt for adult patients with primary open-angle glaucoma who have failed prior medical and surgical treatments. The ab-externo glaucoma drainage device is made from a proprietary SIBS material and designed to lower intraocular pressure (IOP) via a minimally invasive procedure.
The prospective, multi-center, single-arm trial enrolled at least 110 patients across sites in the United States and Canada. The primary effectiveness endpoint is a ≥20% reduction in mean diurnal IOP at 12 months without increasing IOP-lowering medication classes. Glaukos plans to use the results to support a future FDA marketing submission and holds exclusive development and commercialization rights for several markets, including the U.S., Canada, Australia, Brazil, Mexico and New Zealand.
Glaukos (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company, plans to release its second quarter 2026 financial results after the market close on Wednesday, July 29, 2026.
Management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET), with access via the investor website and phone dial-in.
Glaukos (NYSE:GKOS) completed patient enrollment in its Phase 2 trial of GLK-321 for Demodex blepharitis. GLK-321 uses the proprietary iLution cream-based eyelid drug-delivery platform with physostigmine as the active ingredient.
The U.S. study randomized 275 patients; the primary endpoint is collarette elimination after six weeks.
Glaukos (NYSE:GKOS) announced management participation in several investor conferences in May and June 2026, including events hosted by Stifel, William Blair, Jefferies, and Truist.
Live and archived webcasts, where available, will be accessible through the Investors section of the Glaukos website.
Glaukos (NYSE: GKOS) reported Q1 2026 net sales of $150.6 million, up 41% year-over-year (39% constant currency). Glaucoma sales were $129.3 million; U.S. Glaucoma sales were $93.5 million. Gross margin ~78% (non-GAAP ~84%). Raised 2026 revenue guidance to $620–$635 million. Cash and equivalents approx. $280.5 million; no debt.
SG&A rose 32% and R&D rose 36%; GAAP net loss was $19.8 million, non-GAAP net loss $10.4 million.
Glaukos (NYSE: GKOS) published its 2025 Sustainability Report highlighting progress on corporate sustainability, patient access, governance, and operations.
Key metrics: $22 million in product donations to date, ~870 volunteer hours, outreach to ~15,000 patients, ~14,000 keratoconus patients served, FDA approval for Epioxa, groundbroken for a new Huntsville R&D and manufacturing facility, 100% cybersecurity training completion, and external limited assurance of GHG disclosures.
Glaukos (NYSE: GKOS) received a permanent HCPCS J-code J2789 for Epioxa, effective July 1, 2026. The company says the product-specific code should streamline reporting, billing, and payment by U.S. payers over time, supporting market access and the planned commercial launch for keratoconus treatment.
Epioxa is described as an incision-free, oxygen-enriched topical therapy bioactivated by UV light that avoids epithelial removal and aims to reduce pain and recovery versus traditional cross-linking.
Glaukos (NYSE: GKOS) will release first quarter 2026 financial results after the market close on April 29, 2026. Management will host a conference call and simultaneous webcast on April 29 at 1:30 p.m. PT / 4:30 p.m. ET.
Live webcast access is available at http://investors.glaukos.com. U.S. dial-in is 800-715-9871, international 646-307-1963, Conference ID 1333241. A replay will be archived on the company website after the call.